Cipla secured US FDA approval for its generic Advair Diskus®, a key therapy for asthma/COPD.

The US market for this product is ~$908 million.

Expected launch is Q2 FY27. This marks Cipla's first US-made dry powder inhaler approval, significantly boosting its respiratory capabilities and market presence.